Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Characterization of cognitive decline in long-duration type 1 diabetes by cognitive, neuroimaging, and pathological examinations
Hetal S. Shah, Matthew N. DeSalvo, Anastasia Haidar, Surya Vishva Teja Jangolla, Marc Gregory Yu, Rebecca S. Roque, Amanda Hayes, John Gauthier, Nolan Ziemniak, Elizabeth Viebranz, I-Hsien Wu, Kyoungmin Park, Ward Fickweiler, Tanvi J. Chokshi, Tashrif Billah, Lipeng Ning, Atif Adam, Jennifer K. Sun, Lloyd Paul Aiello, Yogesh Rathi, Mel B. Feany, George L. King
Hetal S. Shah, Matthew N. DeSalvo, Anastasia Haidar, Surya Vishva Teja Jangolla, Marc Gregory Yu, Rebecca S. Roque, Amanda Hayes, John Gauthier, Nolan Ziemniak, Elizabeth Viebranz, I-Hsien Wu, Kyoungmin Park, Ward Fickweiler, Tanvi J. Chokshi, Tashrif Billah, Lipeng Ning, Atif Adam, Jennifer K. Sun, Lloyd Paul Aiello, Yogesh Rathi, Mel B. Feany, George L. King
View: Text | PDF
Clinical Research and Public Health Aging Endocrinology

Characterization of cognitive decline in long-duration type 1 diabetes by cognitive, neuroimaging, and pathological examinations

  • Text
  • PDF
Abstract

BACKGROUND We aimed to characterize factors associated with the under-studied complication of cognitive decline in aging people with long-duration type 1 diabetes (T1D).METHODS Joslin “Medalists” (n = 222; T1D ≥ 50 years) underwent cognitive testing. Medalists (n = 52) and age-matched nondiabetic controls (n = 20) underwent neuro- and retinal imaging. Brain pathology (n = 26) was examined. Relationships among clinical, cognitive, and neuroimaging parameters were evaluated.RESULTS Compared with controls, Medalists had worse psychomotor function and recall, which associated with female sex, lower visual acuity, reduced physical activity, longer diabetes duration, and higher inflammatory cytokines. On neuroimaging, compared with controls, Medalists had significantly lower total and regional brain volumes, equivalent to 9 years of accelerated aging, but small vessel disease markers did not differ. Reduced brain volumes associated with female sex, reduced psychomotor function, worse visual acuity, longer diabetes duration, and higher inflammation, but not with glycemic control. Worse cognitive function, lower brain volumes, and diabetic retinopathy correlated with thinning of the outer retinal nuclear layer. Worse baseline visual acuity associated with declining psychomotor function in longitudinal analysis. Brain volume mediated the association between visual acuity and psychomotor function by 57%. Brain pathologies showed decreased volumes, but predominantly mild vascular or Alzheimer’s-related pathology.CONCLUSION To our knowledge, this is the first comprehensive study of cognitive function, neuroimaging, and pathology in aging T1D individuals demonstrated that cognitive decline was related to parenchymal rather than neurovascular abnormalities, unlike type 2 diabetes, suggestive of accelerated aging in T1D. Improving visual acuity could perhaps be an important preventive measure against cognitive decline in people with T1D.FUNDING The Beatson Foundation, NIH/NIDDK grants 3P30DK036836-34S1 and P30DK036836-37, and Mary Iacocca fellowships.

Authors

Hetal S. Shah, Matthew N. DeSalvo, Anastasia Haidar, Surya Vishva Teja Jangolla, Marc Gregory Yu, Rebecca S. Roque, Amanda Hayes, John Gauthier, Nolan Ziemniak, Elizabeth Viebranz, I-Hsien Wu, Kyoungmin Park, Ward Fickweiler, Tanvi J. Chokshi, Tashrif Billah, Lipeng Ning, Atif Adam, Jennifer K. Sun, Lloyd Paul Aiello, Yogesh Rathi, Mel B. Feany, George L. King

×

Figure 1

Associations of clinical characteristics with cognitive function in T1D (n = 222).

Options: View larger image (or click on image) Download as PowerPoint
Associations of clinical characteristics with cognitive function in T1D ...
Heatmaps showing bivariate standardized estimates of associations between clinical characters as independent variables and cognitive function domains as dependent variables in linear regression models. The estimates represent changes in cognitive function per 1 SD change in the clinical predictor. Color and intensity represent the strength and direction (positive, zero or no, and negative) of association. Better cognitive function is represented by more blue estimates, and worse by red. MIS, memory index score. Blank squares not significant. *P < 0.05, **P < 0.01, ***P < 0.0001. (A) Markers of sociodemographics and lifestyle. (B) Glycemic markers. Life.Hypog, lifetime hypoglycemia severity; CV, coefficient of variation of glucose on CGM; TAR>250, time above range of glucose > 250 mg/dL; TIR 70–180, time-in-range 70–180 mg/dL; TBR<70, time below range of glucose < 70 mg/dL; CEL, CML, and MGH1 are advanced glycation end products. (C) Cardiometabolic markers. DBP and SBP, diastolic and systolic blood pressure; CRP, C-reactive protein; IL, interleukin; IFN-γ, interferon γ; TNF-α, tumor necrosis factor α. (D) Insulin resistance markers. BMI, body mass index; eGDR, estimated glucose disposal rate; eIS, estimated insulin sensitivity; VAI, visceral adiposity index; TG:HDL, triglyceride/HDL ratio; WHR, waist/hip ratio. (E) Complications. ACR, urine albumin/creatinine ratio; eGFR, estimated glomerular filtration rate; D and ND, dominant and nondominant hands; DN, diabetic nephropathy; RHA, reduced hypoglycemia awareness; DPN, diabetic peripheral neuropathy; AN, autonomic neuropathy; CVD, cardiovascular disease; CAC, coronary artery calcification; VA, visual acuity; PDR, proliferative diabetic retinopathy.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts